Trial Information

Summary: Ziprasidone augmentation in serotonin reuptake inhibitor-resistant Obsessive-Compulsive Disorder

The purpose of this study is to determine whether the medication ziprasidone (Geodon) added to a serotonin reuptake inhibitor (SRI) is effective in the treatment of patients who have previously experienced little or no response to SRI treatment of Obsessive-Compulsive Disorder. Ziprasidone is approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia, but not approved for the symptoms associated with obsessive-compulsive disorder. Study volunteers will be randomly assigned to receive either ziprasidone or placebo (sugar pill) in addition to their SRI for a period of 8 weeks. Study volunteers will have a 50% chance of being given active medication. Assessments included in the study will be: a psychiatric and medical evaluation, lab tests (physical exam, routine blood test, urinalysis, urine drug screen, an electrocardiogram (EKG) and a blood pregnancy test (females only).) Participants will be closely monitored throughout the study by a psychiatrist. GCO# 02-0150
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

Men and women aged 18 - 65 years who have had little or no response to more than 1 prior trial with an SRI will be eligible to enter the program. Study volunteers should have a primary diagnosis of Obsessive-Compulsive Disorder and should be physically healthy without any serious medical, psychiatric, or neurological illnesses other than OCD. Study volunteers should be stable on an SRI for at least 3 months prior to enrollment.

Study volunteers should not be on any other forms of psychiatric medication other than an SRI; those on other medications must be willing to come off their medication. Please contact the Study Coordinator below for further exclusion criteria.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.